These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 12556438)
1. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. Lonks JR; Garau J; Medeiros AA J Antimicrob Chemother; 2002 Dec; 50 Suppl S2():87-92. PubMed ID: 12556438 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Lynch III JP; Martinez FJ Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]
5. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes? Rothermel CD Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368 [TBL] [Abstract][Full Text] [Related]
6. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?). Low DE Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867 [TBL] [Abstract][Full Text] [Related]
7. Drug treatment of pneumococcal pneumonia in the elderly. Neralla S; Meyer KC Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections. Marrie TJ Int J Clin Pract; 2004 Aug; 58(8):769-76. PubMed ID: 15372850 [TBL] [Abstract][Full Text] [Related]
9. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. File TM; Tan JS Drugs; 2003; 63(2):181-205. PubMed ID: 12515565 [TBL] [Abstract][Full Text] [Related]
10. Macrolide resistance in Streptococcus pneumoniae isolated from patients with community-acquired lower respiratory tract infections in Portugal: results of a 3-year (1999-2001) multicenter surveillance study. Melo-Cristino J; Ramirez M; Serrano N; Hänscheid T; Microb Drug Resist; 2003; 9(1):73-80. PubMed ID: 12705685 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497 [TBL] [Abstract][Full Text] [Related]
12. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Lonks JR; Garau J; Gomez L; Xercavins M; Ochoa de Echagüen A; Gareen IF; Reiss PT; Medeiros AA Clin Infect Dis; 2002 Sep; 35(5):556-64. PubMed ID: 12173129 [TBL] [Abstract][Full Text] [Related]
13. Genotyping and serotyping of macrolide and multidrug resistant Streptococcus pneumoniae isolated from carrier children. Swedan SF; Hayajneh WA; Bshara GN Indian J Med Microbiol; 2016; 34(2):159-65. PubMed ID: 27080766 [TBL] [Abstract][Full Text] [Related]
14. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995 [TBL] [Abstract][Full Text] [Related]
15. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Pihlajamäki M; Kotilainen P; Kaurila T; Klaukka T; Palva E; Huovinen P; Clin Infect Dis; 2001 Aug; 33(4):483-8. PubMed ID: 11462184 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076 [TBL] [Abstract][Full Text] [Related]
17. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Hoban DJ; Zhanel GG Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414 [TBL] [Abstract][Full Text] [Related]
18. [Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China]. Yin YD; Cao B; Wang H; Wang RT; Liu YM; Gao Y; Qu JX; Han GJ; Liu YN Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):954-8. PubMed ID: 24503430 [TBL] [Abstract][Full Text] [Related]
19. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Varon E; Levy C; De La Rocque F; Boucherat M; Deforche D; Podglajen I; Navel M; Cohen R Clin Infect Dis; 2000 Aug; 31(2):477-81. PubMed ID: 10987708 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community]. Guchev IA; Klochkov OI; Ivanitsa GV; Pervov IuA; Shturmina SM; Rosman SV Antibiot Khimioter; 2004; 49(8-9):34-5, 37-42. PubMed ID: 15727144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]